1 / 8

Oligonucleotide Synthesis Market Global Analysis 2022 – 2026

The report "Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026", is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6% during the forecast period. The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine.

Health9000
Download Presentation

Oligonucleotide Synthesis Market Global Analysis 2022 – 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MarketsandMarkets Presents Oligonucleotide Synthesis Market worth $14.1 billion by 2026 https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-synthesis-market-200829350.html

  2. The report "Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026", is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6% during the forecast period. The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownload

  3. Objectives of the Study: • The hospital segment accounted for the largest share of the end user segment in the oligonucleotide synthesis • The PCR sub segment accounted for the largest share of the research application segment • The Asia Pacific region is the fastest growing region • In 2020, the Asia Pacific region accounted for the fasted growing region of the oligonucleotide synthesis market. Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth. • Speak to Analyst: https://www.marketsandmarkets.com/

  4. The study categorizes the oligonucleotide synthesis market into the following segments and subsegments: • Oligonucleotide synthesis Market, by Product • Oligonucleotide-based Drugs • Synthesized Oligonucleotides • By Product • Primers • Probes • DNA Oligos • RNA Oligos • Other Synthesized Oligos • By Type • Customized Oligos • Predesigned Oligos • Reagents • Equipment • Oligonucleotide synthesis Market, by Application • Research Applications • PCR • Sequencing • Other Research Applications • Diagnostic Applications

  5. Some of the leading players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), and Agilent Technologies, Inc. (US). The leading players in the oligonucleotide therapeutics market are Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).

  6. Companies Insight Danaher is one of the key players in the oligonucleotide synthesis market, owing to its robust product portfolio and brand recognition. The two largest acquisitions of IDT (US) and Cytiva (US) enhanced Danaher’s oligonucleotide product offering. The company now offers synthesized oligos such as primers & probes and the raw materials used to synthesize oligos such as reagents and equipment. Danaher’s key growth strategy is introducing active product launches. For instance, in 2019, the company launched the longest (up to 350 mers in length), high quality, and ready-to-use custom oligo pools in the market. Such strategic developments help the company sustain its position in the oligonucleotide synthesis market. Thermo Fisher Scientific (US) led the oligonucleotide synthesis market with a share of 21.4% in 2020. The company has an exhaustive product portfolio consisting of primers, probes, custom oligos, phosphoramidites, reagents, and custom oligo modification. It has adopted various organic and inorganic growth strategies to strengthen its market position. For instance, in 2019, Thermo Fisher supported BioNTechs (Germany) messenger RNA (mRNA) manufacturing platform by supplying nucleotides, enzymes, reagents, and other critical raw materials to expand their manufacturing capacities. Despite the pandemic, the company witnessed a substantial increase in the revenue of its Life Sciences segment as compared to 2019. Increasing revenues in the company’s business were primarily driven by the demand for COVID-19 testing with higher sales of bioproduction products and genetic sciences, which include oligonucleotide products.

  7. Contact Us Contact:Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee Road, Suite 430 Northbrook, IL 60062 USA : 1-888-600-6441 sales@marketsandmarkets.com Press release: https://www.marketsandmarkets.com/PressReleases/oligonucleotide-synthesis.asp Research insights: https://www.marketsandmarkets.com/ResearchInsight/oligonucleotide-synthesis-market.asp

  8. About MarketsandMarkets MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

More Related